Fulgent Genetics (FLGT) Cash & Equivalents (2015 - 2026)

Fulgent Genetics has reported Cash & Equivalents for 12 years, with the latest figure at $26.3 million in Q2 2026.

• Quarterly Cash & Equivalents fell 70.07% year-over-year to $26.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $26.3 million (down 70.07% YoY) and the FY2025 annual result came in at $50.2 million, down 8.98% from the prior year.
• Cash & Equivalents advanced to $26.3 million in Q2 2026 per FLGT's latest filing, from $23.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $353.1 million in Q1 2022 and troughed at $23.4 million in Q1 2026.
• A 5-year average of $91.8 million and a median of $66.7 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 133.11% in 2022, then slumped 81.26% in 2023.
• Over 5 years, Cash & Equivalents stood at $79.5 million in 2022, then climbed by 22.6% to $97.5 million in 2023, then sank by 43.43% to $55.1 million in 2024, then retreated by 8.98% to $50.2 million in 2025, then sank by 47.59% to $26.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $26.3 million, $23.4 million, and $50.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.